PPT-Therapy for COPD: Can They Afford It?

Can They Use It Linda Sobeski PharmD BCPS Clinical Associate Professor Department of Pharmacy Practice and Science UNMC College of Pharmacy Objectives Errors related to device mishandling are common in COPD. Kathleen McNamara, . PharmD. PGY1 Pharmacy Resident 2015-2016 NEIMEF & WHC. Therapy Goals & Assessment. Non-pharmacologic & Pharmacologic Therapy. Medications. Mechanism of Action. Adverse Effects. COPD is characterized by :. **Chronic airflow obstruction & accelerated . . loss of lung function which is progressive & . NOT. fully reversible.. ** COPD is preventable & treatable but . Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of . New Clinical Data?. Program Overview. Managing Stable COPD: Goals of Therapy. Updated GOLD Recommendations: . First-line Pharmacologic Therapy for Stable COPD. Dr Maxine Hardinge. Consultant Respiratory . Medicine . Oxford . University Hospitals NHS Foundation Trust. Aims of treatment – reducing risk and reducing symptoms. Inhaled therapy – . new Oxfordshire . Julia Rogers, MSN, RN, CNS, FNP-BC. Diagnosis and Overview. Therapeutic . Options. Manage Stable COPD. Manage . Exacerbations. . Airway and systemic inflammation. Under-recognized / under-diagnosed. Dietetic Intern. Andrews University. Introduction. Patient’s Initials: NM. Primary . Problem . & other . medical conditions: . COPD. , DM, IBS, Pneumonia, IgA . deficiency. Height: 160.02. Weight: 107.2. Patient Background. Daishi . Hayato. Age 65. Male. Asian American. Retired. Wife and 4 adult children. Father had lung cancer . Primary Diagnosis: . Acute respiratory distress, COPD, peripheral vascular disease with intermittent . Objectives of Treatment. GOLD 2018: Pharmacologic Treatment Recommendations. GOLD 2018: Pharmacologic Treatment Recommendations (. c. ont). GOLD 2018: Pharmacologic Treatment Recommendations in Groups C and D. Clinical Trial Evidence. Introduction . Therapeutic Recommendations . Therapeutic Recommendations in Groups B and D . Bronchodilators in Stable COPD. ICS in Stable COPD. COPD . Potential AEs of ICS Treatment. according to GOLD 2006 and 2011 revisions. . Ivan Vyshnyvetskyy. 1. , Yuriy Mostov. o. y. 2. , Olexiy Onyshchenko. 1. 1 – . Department of. Internal Medicine and General Practice - Family Medicine, Donetsk National Medical University, Donetsk, Ukraine,. in the Treatment of . Asthma and COPD. Margaret Miklich, . PharmD. , BCACP. Clinical Assistant Professor. 1. m. argaret.miklich@temple.edu. I have no conflicts of interest to disclose.. 2. Pharmacist Objectives. in the Treatment of . Asthma and COPD. Margaret Miklich, . PharmD. , BCACP. Clinical Assistant Professor. 1. m. argaret.miklich@temple.edu. I have no conflicts of interest to disclose.. 2. Pharmacist Objectives. inspiration to keep your airways open, and the lower pressure (EPAP)is delivered when you exhale.Some people who are ordereda very high pressure to relieve their apneas may find it difficult to breath disease . is characterized by . . airflow limitation that is not fully . reversible.. The . airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases. .